Analysts Set Masimo Co. (NASDAQ:MASI) PT at $167.00

Masimo Co. (NASDAQ:MASI) has earned an average rating of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $167.00.

A number of research analysts have recently commented on MASI shares. BTIG Research boosted their target price on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Wednesday, November 6th. Piper Sandler raised their target price on Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Wells Fargo & Company boosted their price target on Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. Finally, Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price objective for the company in a research note on Wednesday, November 6th.

Institutional Trading of Masimo

Several institutional investors and hedge funds have recently bought and sold shares of MASI. Tidal Investments LLC lifted its position in shares of Masimo by 14.1% in the 1st quarter. Tidal Investments LLC now owns 2,179 shares of the medical equipment provider’s stock worth $320,000 after buying an additional 269 shares during the last quarter. GAMMA Investing LLC lifted its stake in Masimo by 75.0% in the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 111 shares during the last quarter. M&G Plc boosted its holdings in shares of Masimo by 4.8% during the second quarter. M&G Plc now owns 3,240 shares of the medical equipment provider’s stock valued at $408,000 after acquiring an additional 149 shares during the period. 180 Wealth Advisors LLC grew its position in shares of Masimo by 26.1% during the second quarter. 180 Wealth Advisors LLC now owns 2,721 shares of the medical equipment provider’s stock worth $343,000 after acquiring an additional 563 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Masimo by 643.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 50,740 shares of the medical equipment provider’s stock worth $6,390,000 after acquiring an additional 43,918 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Stock Down 0.2 %

Shares of NASDAQ MASI opened at $169.52 on Friday. The stock has a fifty day moving average price of $154.07 and a 200 day moving average price of $131.87. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo has a 12-month low of $101.35 and a 12-month high of $178.27. The company has a market cap of $9.08 billion, a P/E ratio of 116.91 and a beta of 1.01.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The business had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.63 earnings per share. Research analysts anticipate that Masimo will post 4.03 EPS for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.